| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/28/2010 | US7803784 Modulation of T cell signaling threshold and T cell sensitivity to antigens |
| 09/28/2010 | US7803766 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; long-acting action |
| 09/28/2010 | US7803752 Method of inducing neuronal production in the caudate nucleus and putamen |
| 09/28/2010 | US7803637 Compositions and methods for treatment of neoplastic disease |
| 09/28/2010 | US7803618 nucleic acid encoding an anti-EpCAM protein; binds human epithelial cell adhesion molecule; immunoglobulin light chain region modified to reduce immunogenicity; diagnosis, prognosis and treatment of cancer |
| 09/28/2010 | US7803615 Death domain containing receptor 5 |
| 09/28/2010 | US7803614 isolated host cell transfected with the recombinant expression vector encoding an immunogenic protein; diagnosis of skin cancer; vaccine for prevent and treatment; immunotherapy |
| 09/28/2010 | US7803613 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 09/28/2010 | US7803583 based on reduction of terminal sialic acid residues on saccharides, with DP then being calculated by comparing the molar ratio of total sialic acid to reduced sialic acid |
| 09/28/2010 | US7803566 Identifying T-cells in a sample that become activated in the presence of an amino acid sequence of a peptide with the same function as a CD8 T cell epitope of a vaccinia or variola virus; diagnosing vaccinia or variola virus infection by determining if the T-cells are activated by the peptide |
| 09/28/2010 | US7803562 Method for screening human intestinal Npt2B modulatory agents |
| 09/28/2010 | US7803555 Determining the effect of a test compound on the binding interaction between a folate receptor and a folate receptor-binding fragment of a filovirus envelope glycoprotein; a compound that reduces binding is a candidate compound for slowing the progression of a filovirus, e.g., Ebola, mediated disease |
| 09/28/2010 | US7803524 Diagnostic compositions containing the polypeptide conjugated to a detectable label, such as radioisotopes, enzymes, fluorescent labels, antibody conjugates, or substrates |
| 09/28/2010 | US7803389 Toxoplasma gondii mutant with enhanced homologous recombination and uses thereof |
| 09/28/2010 | US7803388 Polymorphic membrane proteins or PMPs of Chlamydia, amino acid and nucleotide sequences; immunogens; vaccines; biodrugs;respiratory system disorders; urogenital system disorders; genetic engineering |
| 09/28/2010 | US7803387 With proteins of nisseria and purification of domains and gene expression of oligopeptides of ser, lys, ala, glu, gly and met |
| 09/28/2010 | US7803386 An immunogenic conjugate comprising a synthetic homopolymer of poly- gamma -glutamic acidpolypeptide covalently linked to a carrier, where the conjugate elicits an immune response against poly- gamma -glutamic acid ( gamma PGA) polypeptide; vaccine with fewer dosages; anthrax; diptheria |
| 09/28/2010 | US7803383 Method of treatment comprising administration of a cytokine antagonist molecule |
| 09/28/2010 | US7803382 Using human leukocyte antigen class I-binding peptide as immune modulator which enhances cancer cell targeting; immunotherapy |
| 09/28/2010 | US7803381 Synthetic peptide comprising the amino acid sequence GPRLGYSWHX in which each of the amino acids are in the D-amino acid configuration and X is any amino acid; optionally conjugated to the natural gonadotropin-releasing hormone peptide; vaccines for use incontrolling fertility or heat in an animal |
| 09/28/2010 | US7803380 Reducing the growth of an osteopontin-expressing tumor cell, such as metastatic hepatocellular carcinoma, by administering a peptide that reduces cellular invasion resulting from the interaction between a fragment of OPN generated by metalloproteinase-9 cleavage and CD44 receptor; diagnosis by OPN level |
| 09/28/2010 | US7803379 Tumour-specific animal proteins |
| 09/28/2010 | US7803378 Antigen imitating extracellular areas of membrane proteins of type III produced from intracellular pathogenic micro-organisms, derived conformational antibodies and the use thereof |
| 09/28/2010 | US7803377 Anti-DLL4 antibodies and methods using same |
| 09/28/2010 | US7803376 Synergistic mixture of a blocking agent of an inhibitory receptor or stimulant of an activating receptor of natural killer cells and an antibody that can be bound by the CD16 antigen; efficiency is enhanced through the increase of the antibody-dependent cellular cytoxicity mechanism |
| 09/28/2010 | US7803375 Reducing leakage from unwanted choroidal neovasculature by administering an anti-FasL factor to permit an effective amount to localize in the neovasculature, administering a photosensitizer to the neovasculature, and irradiating it with laser light; photodynamic therapy |
| 09/28/2010 | US7803374 Targeted atherosclerosis treatment |
| 09/28/2010 | US7803373 Chemokine panec-1 antibodies |
| 09/28/2010 | US7803372 Mixture of anti-CEA (carcinogenicembryonic antigen) monoclonal antibody (MAb) or fragment and drug |
| 09/28/2010 | US7803371 Anti-VEGF antibody |
| 09/28/2010 | US7803370 Method for treating synovial sarcoma |
| 09/28/2010 | US7803365 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 09/28/2010 | US7803363 Attenuated Francisella bacteria |
| 09/28/2010 | US7803361 Decreasing solid tumor size in a cancer patient by administering an interleukin-2 mutant with reduced vasopermeability activity compared to a wildtype form, and being Arg38Trp, wherein said wildtype form is human IL-2 mutant and the IL-2 mutant is not linked to an antibody. |
| 09/28/2010 | US7803183 Medical device with coating that promotes endothelial cell adherence |
| 09/28/2010 | CA2380298C Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
| 09/28/2010 | CA2371994C Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
| 09/28/2010 | CA2326821C Nucleic acid encoding hyaluronan synthase and methods of use |
| 09/28/2010 | CA2308201C Use of anti-fungal agents for the treatment of fungus-induced mucositis |
| 09/28/2010 | CA2286288C Monoclonal antibody recognizing the n-glycolylated-galacotose-glucose sialic acid oligosaccharide in malignant tumors and composition that contains it |
| 09/28/2010 | CA2285746C Osteoprotegerin binding proteins and receptors |
| 09/28/2010 | CA2235866C Methods of treating established colitis using antibodies against il-12 |
| 09/28/2010 | CA2208783C Methods for producing immunoglobulins containing protection proteins in plants and their use |
| 09/28/2010 | CA2153494C Novel parasitic helminth proteins |
| 09/23/2010 | WO2010108182A2 Production of recombinant proteins in ciliates and uses thereof |
| 09/23/2010 | WO2010108177A2 A method and composition using a dual specificity protein tyrosine phosphatase as an antimalarial drug target |
| 09/23/2010 | WO2010108153A2 Carrier immunoglobulins and uses thereof |
| 09/23/2010 | WO2010108048A2 Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| 09/23/2010 | WO2010108001A2 Agents and methods for tissue repair and regeneration |
| 09/23/2010 | WO2010107939A2 Human immunodeficiency virus (hiv) -neutralizing antibodies |
| 09/23/2010 | WO2010107909A2 Methods and compositions for the detection of cancer |
| 09/23/2010 | WO2010107847A1 Replication-defective flavivirus vaccine vectors against respiratory syncytial virus |
| 09/23/2010 | WO2010107778A1 Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
| 09/23/2010 | WO2010107658A2 Methods and compositions for bi-specific targeting of cd19/cd22 |
| 09/23/2010 | WO2010107120A1 Antibody and anti-periodontal disease composition containing antibody |
| 09/23/2010 | WO2010107110A1 Antibody constant region variant |
| 09/23/2010 | WO2010107109A1 Antibody constant region variant |
| 09/23/2010 | WO2010107108A1 Rheumatoid arthritis treatment agent |
| 09/23/2010 | WO2010106812A1 Pharmaceutical formulation containing improved antibody molecules |
| 09/23/2010 | WO2010106770A1 Neil3 peptides and vaccines including the same |
| 09/23/2010 | WO2010106187A2 Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders |
| 09/23/2010 | WO2010106127A2 Method for therapeutic use |
| 09/23/2010 | WO2010106095A1 In situ constituting a vaccine for administration to a predetermined herd of animals |
| 09/23/2010 | WO2010105446A1 A human anti-tumor necrosis factor alpha monoclonal antibody and use thereof |
| 09/23/2010 | WO2010105347A1 Vaccination methods |
| 09/23/2010 | WO2010105298A1 Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof |
| 09/23/2010 | WO2010105290A1 Humanised antibodies with anti-tumour activity |
| 09/23/2010 | WO2010086189A3 Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| 09/23/2010 | WO2010062143A3 Anticancer composition comprising antitumor agent and substance having inhibitory effects on l1cam activity and expression |
| 09/23/2010 | WO2010036959A3 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| 09/23/2010 | WO2010031720A3 Novel antibody formulation |
| 09/23/2010 | WO2009114869A3 Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis |
| 09/23/2010 | US20100240876 Replikins and methods of identifying replikin-containing sequences |
| 09/23/2010 | US20100240875 Antibodies That Specifically Bind to Reg IV |
| 09/23/2010 | US20100240873 Ligand (act-4-l) to a receptor on the surface of activated cd4+ tcells |
| 09/23/2010 | US20100240100 Human antibodies that have mn binding and cell adhesion-neutralizing activity |
| 09/23/2010 | US20100239682 Colonic delivery of antimicrobial agents |
| 09/23/2010 | US20100239659 Self-assembling amphiphilic polymers as anti-cancer agents |
| 09/23/2010 | US20100239656 Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders |
| 09/23/2010 | US20100239654 Vesicular phospholipid gels comprising proteinaceous substances |
| 09/23/2010 | US20100239652 Immunoliposomes for treatment of cancer |
| 09/23/2010 | US20100239633 Immunoglobulin constant region fc receptor binding agents |
| 09/23/2010 | US20100239617 Modified rsv f proteins and methods of their use |
| 09/23/2010 | US20100239615 Compositions and methods for the therapy and diagnosis of lung cancer |
| 09/23/2010 | US20100239614 Isolation and Purification of P. Falciparum Merozoite Protein-142 Vaccine |
| 09/23/2010 | US20100239613 Attenuated ehrlichiosis vaccine |
| 09/23/2010 | US20100239612 Method of Immunization Against the 4 Serotypes of Dengue Fever |
| 09/23/2010 | US20100239611 Combination adjuvant formulation |
| 09/23/2010 | US20100239610 Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant |
| 09/23/2010 | US20100239609 Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification |
| 09/23/2010 | US20100239608 PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS |
| 09/23/2010 | US20100239607 Compositions for inducing immune responses |
| 09/23/2010 | US20100239606 Two-Step Temperature Profile for the Propagation of Viruses |
| 09/23/2010 | US20100239605 Recombinant Rhinovirus Vectors |
| 09/23/2010 | US20100239604 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| 09/23/2010 | US20100239601 Method of immunizing humans against salmonella typhi using a vi-repa conjugate vaccine |
| 09/23/2010 | US20100239600 Conjugate purification |
| 09/23/2010 | US20100239599 Vaccine Peptide Combinations Against Cat Allergy |
| 09/23/2010 | US20100239598 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| 09/23/2010 | US20100239597 Anti-ADDL monoclonal antibody and use thereof |